Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Alliance Reg Med.png
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
January 10, 2020 11:23 ET | Alliance for Regenerative Medicine
WASHINGTON, D.C., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $4.50
January 31, 2013 09:15 ET | Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Jan 31, 2013) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) ("ADVENTRX" or "ANX") with a twelve...
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
July 12, 2012 09:15 ET | Vista Partners
SAN FRANCISCO, CA--(Marketwire - Jul 12, 2012) - Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) (NYSE Amex: ANX) ("The Company,"...
Vista Partners Publishes May 2012 Newsletter
May 08, 2012 09:15 ET | Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - May 8, 2012) - Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of May. Each...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
November 04, 2008 09:00 ET | HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
January 17, 2008 09:00 ET | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its first round of venture financing three months ago, today announced that the U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
November 01, 2007 10:30 ET | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company developing proprietary small molecule therapeutics to treat serious blood disorders, today announced that it...